Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Keros Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation is available from November 22, 2021, at 10:00 a.m. ET, and will be archived on Keros' investor website for 90 days. Keros focuses on developing novel treatments for hematological and musculoskeletal disorders, with product candidates including KER-050 for cytopenias and KER-047 for anemia due to iron imbalance.

LEXINGTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the Piper Sandler 33^rd Annual Virtual Healthcare Conference.

A recording of the fireside chat presentation will be available starting on Monday, November 22, 2021 at 10:00 a.m. ET., and will be archived in the Investors section of the Keros website at https://ir.kerostx.com. A replay will be available for 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:
Mike Biega
mbiega@soleburytrout.com
617-221-9660

FAQ

What is Keros Therapeutics focusing on in its development efforts?

Keros Therapeutics focuses on the discovery and development of novel treatments for hematological and musculoskeletal disorders with high unmet medical need.

When will Keros Therapeutics' CEO present at the Piper Sandler conference?

Keros Therapeutics' CEO, Jasbir S. Seehra, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET.

How can I access the Keros Therapeutics conference presentation?

A recording of the Keros Therapeutics presentation will be available on their investor website starting November 22, 2021, and will be archived for 90 days.

What are the key product candidates of Keros Therapeutics?

Keros Therapeutics’ key product candidates include KER-050 for cytopenias, KER-047 for anemia due to iron imbalance, and KER-012 for disorders associated with bone loss.

What types of disorders does Keros Therapeutics aim to address?

Keros Therapeutics aims to address hematological disorders, such as anemia and thrombocytopenia, as well as musculoskeletal disorders.